Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for ertugliflozin in Any Name (approximate match)

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Ertugliflozin

6C282481IP

Search for Structure

Status:

US Approved Rx (2017)

Source:

NDA209806

(2017)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806

First approved in 2017

Source:

NDA209806

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/glucose cotransporter 1

Sodium/glucose cotransporter 2

Conditions:

Type 2 diabetes mellitus

type 2 diabetes mellitus

Ertugliflozin (PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. SGLT2 has become an important therapeutic target and several SGLT2-selective inhibitors are either approved or in clinical development for the management of blood glucose in patients with type 2 diabetes. Ertugliflozin demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It was announced that FDA and EMA filing acceptances of three marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes.

Keto ertugliflozin

AS4THB3PTC

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Ertugliflozin tetrapropionate

Z3Z7MGA68Y

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(2S,3R,4S,5S)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol

YV4YK89UZP

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

ERTUGLIFLOZIN-3-O-GLUCURONIDE

U7X2VQX83T

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

PF-06685948

3G8R6SUZ3C

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

1,6-Anhydro-1-C-[4-chloro-3-[(S)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

5U4GBN5SYC

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

1,6-Anhydro-1-C-[4-chloro-3-[(R)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

3489DB65ZM

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

ERTUGLIFLOZIN METABOLITE M1

3N9MP29ETS

Status:

Other

Class:

MIXTURE

Ertugliflozin pidolate

MLU731K321

Search for Structure

Status:

US Approved Rx (2017)

Source:

NDA209806

(2017)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806

First approved in 2017

Source:

NDA209806

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209806

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sodium/glucose cotransporter 1

Sodium/glucose cotransporter 2

Conditions:

Type 2 diabetes mellitus

type 2 diabetes mellitus

Ertugliflozin (PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. SGLT2 has become an important therapeutic target and several SGLT2-selective inhibitors are either approved or in clinical development for the management of blood glucose in patients with type 2 diabetes. Ertugliflozin demonstrated robust urinary glucose excretion in rats and an excellent preclinical safety profile. It was announced that FDA and EMA filing acceptances of three marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes.

Structure of Ertugliflozin

ABSOLUTE

Structure of Keto ertugliflozin

ABSOLUTE

Keto ertugliflozin

Structure of Ertugliflozin tetrapropionate

ABSOLUTE

Ertugliflozin tetrapropionate

Structure of (2S,3R,4S,5S)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol

ABSOLUTE

(2S,3R,4S,5S)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol

Structure of ERTUGLIFLOZIN-3-O-GLUCURONIDE

ABSOLUTE

ERTUGLIFLOZIN-3-O-GLUCURONIDE

Structure of PF-06685948

ABSOLUTE

Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(S)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

ABSOLUTE

1,6-Anhydro-1-C-[4-chloro-3-[(S)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(R)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

ABSOLUTE

1,6-Anhydro-1-C-[4-chloro-3-[(R)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose

Mixture

ERTUGLIFLOZIN METABOLITE M1

Structure of Ertugliflozin pidolate

ABSOLUTE

Ertugliflozin pidolate

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1